Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

Layton, Mark E.; Kern, Jeffrey C.; Hartingh, Timothy J.; Shipe, William D.; Raheem, Izzat; Kandebo, Monika; Hayes, Robert P.; Huszar, Sarah; Eddins, Donnie; Ma, Bennett; Fuerst, Joy; Wollenberg, Gordon K.; Li, Jing; Fritzen, Jeff; McGaughey, Georgia B.; Uslaner, Jason M.; Smith, Sean M.; Coleman, Paul J.; Cox, Christopher D.

doi:10.1021/acs.jmedchem.2c01521

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

Journal Article · 09 January 2023 · Journal of Medicinal Chemistry

DOI:https://doi.org/10.1021/acs.jmedchem.2c01521· OSTI ID:2423389

^[1]; Kern, Jeffrey C. ^[1]; Hartingh, Timothy J. ^[1]; ^[1]; ^[1]; Kandebo, Monika ^[2]; Hayes, Robert P. ^[3]; Huszar, Sarah ^[4]; Eddins, Donnie ^[4]; Ma, Bennett ^[5]; Fuerst, Joy ^[6]; Wollenberg, Gordon K. ^[7]; Li, Jing ^[8]; Fritzen, Jeff ^[8]; ^[9]; ^[2]; Smith, Sean M. ^[2]; Coleman, Paul J. ^[1]; Cox, Christopher D. ^[1]

Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
Neuroscience, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
Structural Chemistry, Merck & Co., Inc., Boston, Massachusetts 02115, United States
In Vivo Pharmacology, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
Pharmacokinetics, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
Discovery Pharmaceutical Sciences, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
Nonclinical Drug Safety, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
Discovery Process Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States
Chemistry Modeling and Informatics, Merck & Co., Inc., West Point, Pennsylvania 19486, United States

Not provided.

Research Organization:: Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: USDOE

DOE Contract Number:: AC02-06CH11357

OSTI ID:: 2423389

Journal Information:: Journal of Medicinal Chemistry, Journal Name: Journal of Medicinal Chemistry Journal Issue: 2 Vol. 66; ISSN 0022-2623

Publisher:: American Chemical Society (ACS)

Country of Publication:: United States

Language:: English

References (24)

Discovery of [ 11 C ] MK - 8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors Cox, Christopher D.; Hostetler, Eric D.; Flores, Broc A. Bioorganic & Medicinal Chemistry Letters, Vol. 25, Issue 21 https://doi.org/10.1016/j.bmcl.2015.05.080	journal	November 2015
Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics Bradford, Andrea M.; Savage, Kevin M.; Jones, Declan N. C. Psychopharmacology, Vol. 212, Issue 2 https://doi.org/10.1007/s00213-010-1938-0	journal	July 2010
Data processing and analysis with the autoPROC toolbox Vonrhein, Clemens; Flensburg, Claus; Keller, Peter Acta Crystallographica Section D Biological Crystallography, Vol. 67, Issue 4 https://doi.org/10.1107/S0907444911007773	journal	March 2011
Automation of In Vitro Dose-Inhibition Assays Utilizing the Tecan Genesis and an Integrated Software Package to Support the Drug Discovery Process Mosser, S. Journal of the Association for Laboratory Automation, Vol. 8, Issue 4 https://doi.org/10.1016/S1535-5535(04)00281-3	journal	August 2003
Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs Doan, Kelly M. Mahar; Humphreys, Joan E.; Webster, Lindsey O. Journal of Pharmacology and Experimental Therapeutics, Vol. 303, Issue 3 https://doi.org/10.1124/jpet.102.039255	journal	December 2002
Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis Shipe, William D.; Sharik, Steven S.; Barrow, James C. Journal of Medicinal Chemistry, Vol. 58, Issue 19 https://doi.org/10.1021/acs.jmedchem.5b00983	journal	September 2015
Emerging Biology of PDE10A Wilson, Lindsay; Brandon, Nicholas Current Pharmaceutical Design, Vol. 21, Issue 3 https://doi.org/10.2174/1381612820666140826114744	journal	November 2014
Genetic Deletion and Pharmacological Inhibition of Phosphodiesterase 10A Protects Mice From Diet-Induced Obesity and Insulin Resistance Nawrocki, Andrea R.; Rodriguez, Carlos G.; Toolan, Dawn M. Diabetes, Vol. 63, Issue 1 https://doi.org/10.2337/db13-0247	journal	December 2013
Preclinical Characterization of the Phosphodiesterase 10A PET Tracer [11C]MK-8193 Hostetler, Eric D.; Fan, Hong; Joshi, Aniket D. Molecular Imaging and Biology, Vol. 18, Issue 4 https://doi.org/10.1007/s11307-015-0910-0	journal	November 2015
The Prevalence and Correlates of Nonaffective Psychosis in the National Comorbidity Survey Replication (NCS-R) Kessler, Ronald C.; Birnbaum, Howard; Demler, Olga Biological Psychiatry, Vol. 58, Issue 8 https://doi.org/10.1016/j.biopsych.2005.04.034	journal	October 2005
CO Cross‐Coupling of Activated Aryl and Heteroaryl Halides with Aliphatic Alcohols Maligres, Peter E.; Li, Jing; Krska, Shane W. Angewandte Chemie International Edition, Vol. 51, Issue 36 https://doi.org/10.1002/anie.201203460	journal	August 2012
The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey Smith, Sean M.; Uslaner, Jason M.; Cox, Christopher D. Neuropharmacology, Vol. 64 https://doi.org/10.1016/j.neuropharm.2012.06.013	journal	January 2013
Clearance in Drug Design: Miniperspective Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S. Journal of Medicinal Chemistry, Vol. 62, Issue 5 https://doi.org/10.1021/acs.jmedchem.8b01263	journal	October 2018
P534. Initial Assessment of the Clinical Profile of the PDE10A Inhibitor MK-8189 in Patients With an Acute Episode of Schizophrenia Mukai, Yuki; Lupinacci, Robert; Marder, Stephen Biological Psychiatry, Vol. 91, Issue 9 https://doi.org/10.1016/j.biopsych.2022.02.771	journal	May 2022
Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A Soderling, S. H.; Bayuga, S. J.; Beavo, J. A. Proceedings of the National Academy of Sciences, Vol. 96, Issue 12 https://doi.org/10.1073/pnas.96.12.7071	journal	June 1999
The evolution of antipsychotic switch and polypharmacy in natural practice — A longitudinal perspective Tsutsumi, Chisa; Uchida, Hiroyuki; Suzuki, Takefumi Schizophrenia Research, Vol. 130, Issue 1-3 https://doi.org/10.1016/j.schres.2011.05.013	journal	August 2011
Synthesis of the first sulfur-35-labeled hERG radioligand Raab, Conrad E.; Butcher, John W.; Connolly, Thomas M. Bioorganic & Medicinal Chemistry Letters, Vol. 16, Issue 6 https://doi.org/10.1016/j.bmcl.2005.12.021	journal	March 2006
PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action? Menniti, Frank S.; Chappie, Thomas A.; Schmidt, Christopher J. Frontiers in Neuroscience, Vol. 14 https://doi.org/10.3389/fnins.2020.600178	journal	January 2021
Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1 H -pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia ^† † Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1). Verhoest, Patrick R.; Chapin, Douglas S.; Corman, Michael Journal of Medicinal Chemistry, Vol. 52, Issue 16 https://doi.org/10.1021/jm900521k	journal	August 2009
A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia Macek, Thomas A.; McCue, Maggie; Dong, Xinxin Schizophrenia Research, Vol. 204 https://doi.org/10.1016/j.schres.2018.08.028	journal	February 2019
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use Bender, Andrew T.; Beavo, Joseph A. Pharmacological Reviews, Vol. 58, Issue 3 https://doi.org/10.1124/pr.58.3.5	journal	September 2006
Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia Walling, David P.; Banerjee, Anindita; Dawra, Vikas Journal of Clinical Psychopharmacology, Vol. 39, Issue 6 https://doi.org/10.1097/JCP.0000000000001128	journal	November 2019
Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia Raheem, Izzat T.; Schreier, John D.; Fuerst, Joy Bioorganic & Medicinal Chemistry Letters, Vol. 26, Issue 1 https://doi.org/10.1016/j.bmcl.2015.11.013	journal	January 2016
The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents Gentzel, Renee C.; Toolan, Dawn; Roberts, Rhonda Neuropharmacology, Vol. 99 https://doi.org/10.1016/j.neuropharm.2015.05.024	journal	December 2015

Similar Records

Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies

Journal Article · 2019 · Journal of Medicinal Chemistry · OSTI ID:1577169

Discovery of highly potent, selective, covalent inhibitors of JAK3

Journal Article · 2017 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1397307

Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor

Journal Article · 2024 · Journal of Medicinal Chemistry · OSTI ID:2581513

Related Subjects

Pharmacology & Pharmacy

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

Citation Formats

References (24)

Similar Records

Related Subjects